Antibiotice S.A. Logo

Antibiotice S.A.

Develops and manufactures generic medicines and APIs, specializing in anti-infectives.

ATB | RO

Overview

Corporate Details

ISIN(s):
ROATBIACNOR9
LEI:
315700P5G4O1L6GLMS02
Country:
Romania
Address:
VALEA LUPULUI, 707410 IAȘI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Antibiotice S.A. is a pharmaceutical company specializing in the development and manufacturing of generic medicines. With a history of over 65 years, the company produces a diverse portfolio of products for human use, including finished dosage forms and Active Pharmaceutical Ingredients (APIs). Its offerings have a strong focus on anti-infectives, such as penicillin-derived products. The company operates eight GMP-certified manufacturing lines and holds U.S. FDA approvals for key products, including Nystatin (API), Ampicillin for injection, and Nafcillin. Antibiotice is committed to making valuable medicines accessible and affordable for patients and healthcare professionals, driven by continuous investment in research, quality, and the modernization of its manufacturing technologies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 15:37
ISS
Raport curent de informare a investitorilor
Romanian 1.0 MB
2025-11-07 07:37
Report Publication Announcement
Raport curent de informare a investitorilor
Romanian 546.9 KB
2025-11-06 12:52
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 643.5 KB
2025-11-06 12:49
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 1.0 MB
2025-11-05 10:20
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 291.4 KB
2025-10-03 11:39
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-10-03 11:38
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 1.7 MB
2025-10-01 12:53
Pre-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 2.4 MB
2025-09-23 08:35
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-09-17 15:12
Post-Annual General Meeting Information
Raport curent de informare a investitorilor
Romanian 949.8 KB
2025-09-04 12:29
Notice of Dividend Amount
Plata dividend - RC17
Romanian 2.1 MB
2025-08-13 12:27
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.4 MB
2025-08-06 12:40
Report Publication Announcement
Raport curent de informare a investitorilor
Romanian 137.7 KB
2025-07-24 12:07
Pre-Annual General Meeting Information
Convocarea adunarii generale a actionarilor - RC11
Romanian 1.6 MB
2025-07-09 12:28
Board/Management Information
Raport curent de informare a investitorilor
Romanian 491.4 KB

Automate Your Workflow. Get a real-time feed of all Antibiotice S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Antibiotice S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Antibiotice S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Legend Biotech Corp Logo
Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.
United States of America LEGN
LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America LPCN

Talk to a Data Expert

Have a question? We'll get back to you promptly.